Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654622 · ClinicalTrials.gov registry record
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 175
- Enrollment target
NCT06654622: Completed study, sponsored by City of Hope Medical Center.
NCT06654622 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 175 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06654622 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 175 participants
- Enrollment target
Study Summary
This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.
Primary Outcome
Assessment of tumor recurrence through clinical and imaging evaluations.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2026-02-18 |
What the finished NCT06654622 record still lists
NCT06654622 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06654622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06654622 about?
NCT06654622 is a clinical study titled "Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer". This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for...
What is the current status of trial NCT06654622?
This trial is currently completed. The enrollment target is 175 participants. The study started on 2023-04-01. Estimated completion is 2026-02-18.
Who is sponsoring clinical trial NCT06654622?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI